Glenn Batchelder

Mr. Batchelder’s most recent operational role was as co‑founder and CEO of Civitas Therapeutics (sold to Acorda). Prior to Civitas he served as CEO of BIND Therapeutics (sold to Pfizer) and Acceleron Pharma (NASDAQ:XLRN). He started his biotechnology career at Millennium Pharmaceutical serving in roles of increasing responsibility including SVP of Operations.

Mr. Batchelder also currently serves as Executive Chairs of Synchronicity Pharma and Kantum Bio. He also serves on the boards of The Possible Project and the Michael J. Fox Foundation. He previously served as the Chair of the Board for MassBio. He received a BS in Chemical Engineering from Lehigh University.